113 related articles for article (PubMed ID: 23047832)
21. Lymphocyte-rich classical Hodgkin's lymphoma: clinical presentation and treatment outcome in 100 patients treated within German Hodgkin's Study Group trials.
Shimabukuro-Vornhagen A; Haverkamp H; Engert A; Balleisen L; Majunke P; Heil G; Eich HT; Stein H; Diehl V; Josting A
J Clin Oncol; 2005 Aug; 23(24):5739-45. PubMed ID: 16009944
[TBL] [Abstract][Full Text] [Related]
22. [Prognostic value of beta-2-microglobulin in Hodgkin disease in young adults].
Fleury J; Tortochaux J; Legros M; Cure H; Kwiatkowski F; Ferrière JP; Travade P; Dionet C; Gaillard G; Chassagne J
Bull Cancer; 1994 Jul; 81(7):625-31. PubMed ID: 7742606
[TBL] [Abstract][Full Text] [Related]
23. Serum C-reactive protein levels predict survival in hepatocellular carcinoma.
Nagaoka S; Yoshida T; Akiyoshi J; Akiba J; Torimura T; Adachi H; Kurogi J; Tajiri N; Inoue K; Niizeki T; Koga H; Imaizumi T; Kojiro M; Sata M
Liver Int; 2007 Oct; 27(8):1091-7. PubMed ID: 17845537
[TBL] [Abstract][Full Text] [Related]
24. Prognostic significance of TNF alpha and its p55 soluble receptor in malignant lymphomas.
Warzocha K; Salles G; Bienvenu J; Barbier Y; Bastion Y; Doche C; Rieux C; Coiffier B
Leukemia; 1997 Apr; 11 Suppl 3():441-3. PubMed ID: 9209418
[TBL] [Abstract][Full Text] [Related]
25. Inflammatory prognostic markers in clear cell renal cell carcinoma - preoperative C-reactive protein does not improve predictive accuracy.
Bedke J; Chun FK; Merseburger A; Scharpf M; Kasprzyk K; Schilling D; Sievert KD; Stenzl A; Kruck S
BJU Int; 2012 Dec; 110(11 Pt B):E771-7. PubMed ID: 23134582
[TBL] [Abstract][Full Text] [Related]
26. Analysis of prognostic factors after the first relapse of Hodgkin's disease in 187 patients.
Brice P; Bastion Y; Divine M; Nedellec G; Ferrant A; Gabarre J; Reman O; Lepage E; Fermé C
Cancer; 1996 Sep; 78(6):1293-9. PubMed ID: 8826953
[TBL] [Abstract][Full Text] [Related]
27. [Multi-national therapy study for Hodgkin's disease in children and adolescents GPOH-DH 95. Interim report after 2 1/2 years].
Dörffel W; Albrecht M; Lüders H; Marciniak H; Parwaresch R; Schwarze EW; Trauzeddel R; Havers W; Henze G; Janka-Schaub G; Mann G; Niemeyer C; Pötter R; Schellong G; Selle B; Treuner J; Rühl U
Klin Padiatr; 1998; 210(4):212-9. PubMed ID: 9743955
[TBL] [Abstract][Full Text] [Related]
28. [Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage].
Zou GR; Zhang YJ; Xie FY; Zheng W; Li HX; Xia YF; Lin TY; Lu TX
Ai Zheng; 2006 Dec; 25(12):1543-9. PubMed ID: 17166383
[TBL] [Abstract][Full Text] [Related]
29. Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease.
Albitar M; Vose JM; Johnson MM; Do KA; Day A; Jilani I; Kantarjian H; Keating M; O'Brien SM; Verstovsek S; Armitage JO; Giles FJ
Leuk Res; 2007 Feb; 31(2):139-45. PubMed ID: 16545870
[TBL] [Abstract][Full Text] [Related]
30. Elevated high-sensitivity C-reactive protein, a marker of advanced stage gastric cancer and postgastrectomy disease recurrence.
Woo Y; Hyung WJ; Obama K; Kim HI; Pak KH; Son T; Noh SH
J Surg Oncol; 2012 Mar; 105(4):405-9. PubMed ID: 22025360
[TBL] [Abstract][Full Text] [Related]
31. Elevated preoperative systemic inflammatory markers predict poor outcome in localized soft tissue sarcoma.
Choi ES; Kim HS; Han I
Ann Surg Oncol; 2014 Mar; 21(3):778-85. PubMed ID: 24306668
[TBL] [Abstract][Full Text] [Related]
32. Risk-based combined-modality therapy of pediatric Hodgkin's lymphoma: a retrospective study.
Ali A; Sayed H; Farrag A; El-Sayed M
Leuk Res; 2010 Nov; 34(11):1447-52. PubMed ID: 20599270
[TBL] [Abstract][Full Text] [Related]
33. Prognostic significance of Bcl-2, tumor-associated macrophages, and total neoplastic and inflammatory lymph node involvement in advanced stage classical Hodgkin's lymphoma.
Jakovic LR; Mihaljevic BS; Jovanovic MD; Bogdanovic AD; Andjelic BM; Bumbasirevic VZ
Onkologie; 2012; 35(12):733-9. PubMed ID: 23207618
[TBL] [Abstract][Full Text] [Related]
34. Pre-treatment serum levels of interleukin-10, interleukin-12 and their ratio predict response to therapy and probability of event-free and overall survival in childhood soft tissue sarcomas, Hodgkin's lymphomas and acute lymphoblastic leukemias.
Bien E; Balcerska A; Adamkiewicz-Drozynska E; Rapala M; Krawczyk M; Stepinski J
Clin Biochem; 2009 Jul; 42(10-11):1144-57. PubMed ID: 19376105
[TBL] [Abstract][Full Text] [Related]
35. C-reactive protein level predicts prognosis in patients with muscle-invasive bladder cancer treated with chemoradiotherapy.
Yoshida S; Saito K; Koga F; Yokoyama M; Kageyama Y; Masuda H; Kobayashi T; Kawakami S; Kihara K
BJU Int; 2008 Apr; 101(8):978-81. PubMed ID: 18190628
[TBL] [Abstract][Full Text] [Related]
36. Prognosis of patients with advanced Hodgkin's disease: evaluation of four prognostic models using 344 patients included in the Group d'Etudes des Lymphomes de l'Adulte Study.
Fermé C; Bastion Y; Brice P; Lederlin P; Diviné M; Gabarre J; Assouline D; Ferrant A; Berger F; Lepage E
Cancer; 1997 Sep; 80(6):1124-33. PubMed ID: 9305714
[TBL] [Abstract][Full Text] [Related]
37. [Comparing CHOP, CHOP+HD-MTX,and BFM-90 regimens in the survival rate of children and adolescents with B cell non-Hodgkin's lymphoma].
Sun XF; Su YS; Liu DG; Jiang WQ; He YJ; Lin TY; Huang HQ; Zhang L; Xia ZJ; Li YH; Zhou ZM; Chen XQ; Xia Y; Zhen ZJ; Guan ZZ
Ai Zheng; 2004 Aug; 23(8):933-8. PubMed ID: 15301718
[TBL] [Abstract][Full Text] [Related]
38. [New prognostic factors in the treatment of patients with stage-III Hodgkin's disease].
Girshovich MM; Kanaev SV; Pozharisskiĭ KM; Golovanov SG; Barbashov AI
Vopr Onkol; 2010; 56(4):424-9. PubMed ID: 20968021
[TBL] [Abstract][Full Text] [Related]
39. Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group.
Nogová L; Reineke T; Brillant C; Sieniawski M; Rüdiger T; Josting A; Bredenfeld H; Skripnitchenko R; Müller RP; Müller-Hermelink HK; Diehl V; Engert A;
J Clin Oncol; 2008 Jan; 26(3):434-9. PubMed ID: 18086799
[TBL] [Abstract][Full Text] [Related]
40. Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma.
Saito K; Tatokoro M; Fujii Y; Iimura Y; Koga F; Kawakami S; Kihara K
Eur Urol; 2009 May; 55(5):1145-53. PubMed ID: 18930583
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]